NeoGenomics Inc. (NEO)
| Bid | 7.3 |
| Market Cap | 188.1M |
| Revenue (ttm) | 672.36M |
| Net Income (ttm) | -77.59M |
| EPS (ttm) | -0.61 |
| PE Ratio (ttm) | -11.98 |
| Forward PE | 18.19 |
| Analyst | Buy |
| Ask | 7.31 |
| Volume | 6,169,725 |
| Avg. Volume (20D) | 1,838,139 |
| Open | 6.29 |
| Previous Close | 6.39 |
| Day's Range | 6.26 - 7.47 |
| 52-Week Range | 6.08 - 19.11 |
| Beta | 1.41 |
About NEO
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fl...
Analyst Forecast
According to 12 analyst ratings, the average rating for NEO stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 146.24% from the latest price.
Stock ForecastsEarnings Surprise
22 hours ago · seekingalpha.com
NeoGenomics Q1 Earnings: The Stock Price Drop Is A Gift (Rating Upgrade)NeoGenomics' recent 32.23% stock price decline post-Q1 earnings miss is seen as a buying opportunity due to overreaction and long-term growth potential. Despite a slight revenue miss, the company's lo...
